Factors Influencing a Favorable Outcome for RFA of Huge Benign Thyroid Nodules: Preliminary Results and Short-Term Evaluation

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2023 Dec 22

PMID 38131035

Authors

Chun-Hua Chiu

Sheng-Dean Luo

Pi-Ling Chiang

An-Ni Lin

Cheng-Kang Wang

Chen-Kai Chou

Shun-Yu Chi

Meng-Hsiang Chen

Wei-Che Lin

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to investigate potentially favorable factors influencing the therapeutic success of radiofrequency ablation (RFA) of huge benign thyroid nodules (BTNs) (volume >100 ml) and to evaluate the feasibility of RFA as an alternative treatment modality for patients unable or unwilling to undergo surgery.

Methods: This retrospective study evaluated a total of 868 patients, of which 22 patients had huge BTNs who underwent ultrasound-guided moving shot RFA treatment between May 2017 and January 2022. The huge BTNs were categorized into two groups according to a post-RFA treatment volume reduction ratio (VRR) of >80% and <80% at 6 months. Factors influencing these huge BTNs were reviewed, analyzed, and correlated with treatment effectiveness between the two groups.

Results: The factors influencing an effective VRR included huge BTNs located on the left side (OR 7.875, = 0.03), predominant solid/spongiform nodules (OR 7.875, = 0.03), and higher initial ablation rate (IAR) ( = 0.028). Multivariable logistic regression revealed predominant solid/spongiform nodule and the higher IAR were associated with the advanced VRR.

Conclusion: RFA was effective at decreasing the volume of huge BTNs with an acceptable complication rate. The BTN characteristics correlated with a better VRR at the 6-month short-term follow-up were predominant solid/spongiform BTNs and those with the first time ablation treatment initial ablation rate. Nevertheless, regarding the higher regrowth rate of these groups of patients who may need to be treated more times, RFA can only be a feasible alternative treatment modality for patients unable or unwilling to undergo operation.

Citing Articles

Ultrasound-based radiomics to predict the volume reduction rate of benign thyroid nodules after microwave ablation.

Chen F, Gao Y, Xue Q, Niu X, Zhang X, Zang Y Endocrine. 2024; .

PMID: 39638913 DOI: 10.1007/s12020-024-04125-3.

References

Jacobson J, Middleton W, Allison S, Dahiya N, Lee K, Levine B . Ultrasonography of Superficial Soft-Tissue Masses: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. 2022; 304(1):18-30. DOI: 10.1148/radiol.211101. View

Chen W, Luo S, Chen W, Chou C, Chang Y, Cheng K . The Importance of Nodule Size in the Management of Ruptured Thyroid Nodule After Radiofrequency Ablation: A Retrospective Study and Literature Review. Front Endocrinol (Lausanne). 2021; 12:776919. PMC: 8662308. DOI: 10.3389/fendo.2021.776919. View

Wang J, Wu T, Hu K, Xu W, Zheng B, Tong G . Complications Following Radiofrequency Ablation of Benign Thyroid Nodules: A Systematic Review. Chin Med J (Engl). 2017; 130(11):1361-1370. PMC: 5455047. DOI: 10.4103/0366-6999.206347. View

Papini E, Monpeyssen H, Frasoldati A, Hegedus L . 2020 European Thyroid Association Clinical Practice Guideline for the Use of Image-Guided Ablation in Benign Thyroid Nodules. Eur Thyroid J. 2020; 9(4):172-185. PMC: 7445670. DOI: 10.1159/000508484. View

Orloff L, Noel J, Stack Jr B, Russell M, Angelos P, Baek J . Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section.... Head Neck. 2021; 44(3):633-660. DOI: 10.1002/hed.26960. View

Lim L, Lin W, Chiang P, Huang S, Chen Y, Chang Y . One year follow-up of US-Guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: The first experience in Taiwan. J Formos Med Assoc. 2021; 121(8):1406-1413. DOI: 10.1016/j.jfma.2021.09.026. View

Chen M, Lin W, Luo S, Chiang P, Chen Y, Chen W . Residual, regrowth, and new growth of radiofrequency ablation for benign thyroid nodules of different volumes: two-year follow-up results. Int J Hyperthermia. 2022; 39(1):1172-1178. DOI: 10.1080/02656736.2022.2112305. View

Huh J, Baek J, Choi H, Kim J, Lee J . Symptomatic benign thyroid nodules: efficacy of additional radiofrequency ablation treatment session--prospective randomized study. Radiology. 2012; 263(3):909-16. DOI: 10.1148/radiol.12111300. View

Dietrich C, Muller T, Bojunga J, Dong Y, Mauri G, Radzina M . Statement and Recommendations on Interventional Ultrasound as a Thyroid Diagnostic and Treatment Procedure. Ultrasound Med Biol. 2017; 44(1):14-36. DOI: 10.1016/j.ultrasmedbio.2017.08.1889. View

10.

Kim Y, Rhim H, Tae K, Park D, Kim S . Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid. 2006; 16(4):361-7. DOI: 10.1089/thy.2006.16.361. View

11.

Kim J, Baek J, Lim H, Ahn H, Baek S, Choi Y . 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology. Korean J Radiol. 2018; 19(4):632-655. PMC: 6005940. DOI: 10.3348/kjr.2018.19.4.632. View

12.

Cesareo R, Palermo A, Pasqualini V, Simeoni C, Casini A, Pelle G . Efficacy and safety of a single radiofrequency ablation of solid benign non-functioning thyroid nodules. Arch Endocrinol Metab. 2017; 61(2):173-179. PMC: 10118859. DOI: 10.1590/2359-3997000000246. View

13.

Mauri G, Sconfienza L . Percutaneous ablation holds the potential to substitute for surgery as first choice treatment for symptomatic benign thyroid nodules. Int J Hyperthermia. 2016; 33(3):301-302. DOI: 10.1080/02656736.2016.1257827. View

14.

Chung S, Suh C, Baek J, Park H, Choi Y, Lee J . Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis. Int J Hyperthermia. 2017; 33(8):920-930. DOI: 10.1080/02656736.2017.1337936. View

15.

Guang Y, He W, Luo Y, Zhang H, Zhang Y, Ning B . Patient satisfaction of radiofrequency ablation for symptomatic benign solid thyroid nodules: our experience for 2-year follow up. BMC Cancer. 2019; 19(1):147. PMC: 6375217. DOI: 10.1186/s12885-019-5338-5. View

16.

Spiezia S, Garberoglio R, Milone F, Ramundo V, Caiazzo C, Assanti A . Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid. 2009; 19(3):219-25. DOI: 10.1089/thy.2008.0202. View

17.

Bernardi S, Cavallaro M, Colombin G, Giudici F, Zuolo G, Zdjelar A . Initial Ablation Ratio Predicts Volume Reduction and Retreatment After 5 Years From Radiofrequency Ablation of Benign Thyroid Nodules. Front Endocrinol (Lausanne). 2021; 11:582550. PMC: 7883676. DOI: 10.3389/fendo.2020.582550. View

18.

Hillenbrand A, Cammerer G, Dankesreiter L, Lemke J, Henne-Bruns D . Postoperative swallowing disorder after thyroid and parathyroid resection. Pragmat Obs Res. 2018; 9:63-68. PMC: 6198892. DOI: 10.2147/POR.S172059. View

19.

Deandrea M, Garino F, Alberto M, Garberoglio R, Rossetto R, Bonelli N . Radiofrequency ablation for benign thyroid nodules according to different ultrasound features: an Italian multicentre prospective study. Eur J Endocrinol. 2018; 180(1):79-87. DOI: 10.1530/EJE-18-0685. View

20.

Chung S, Baek J, Choi Y, Lee J . Management strategy for nerve damage during radiofrequency ablation of thyroid nodules. Int J Hyperthermia. 2019; 36(1):204-210. DOI: 10.1080/02656736.2018.1554826. View